Full-Time

Senior Manager Manufacturing Systems Engineering

Automation, Multiple Positions

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$163.3k - $220.9k/yr

+ Annual bonus + Stock-based long-term incentives

Holly Springs, NC, USA

In Person

Bachelor's, Master's, PhD, Associate's

Category
Engineering Management (1)
Required Skills
GMP
Version Control

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A high school diploma or GED and 12 years of engineering and/or project management experience, or an associate’s degree and 10 years of experience, or a bachelor’s degree and 8 years of experience, or a master’s degree and 6 years of experience, or a doctorate degree and 2 years of experience.
  • At least 2 years of direct people-management experience and/or leadership experience leading teams, projects, or programs, or directing resource allocation.
  • Experience with Emerson DeltaV distributed control systems, Siemens DesigoCC, and Allen Bradley programmable logic controllers, including advanced troubleshooting and system integration using OPC, Foundation Fieldbus, and Profibus technologies.
  • Knowledge of automation system design.
  • Experience programming, installing, and managing the lifecycle of automation and field-instrumentation technologies.
  • Experience automating good manufacturing practice biopharmaceutical equipment and systems, including buffer preparation and hold, chromatography, single-use mixing vessels, depth filtration, and solution preparation.
  • Experience integrating automation software from various original equipment manufacturers.
  • Experience programming, designing, installing, and managing the lifecycle of manufacturing process controls, automation, and field-instrumentation technologies.
  • Knowledge of Fieldbus and Profibus technologies.
  • Ability to interpret and apply Good Automated Manufacturing Practice and Good Manufacturing Practice requirements, with familiarity with documentation requirements such as 21 CFR Part 11, ASTM E2500, S88, and S95.
Responsibilities
  • Provide technical and administrative leadership to a group of Automation Engineers responsible for administering and maintaining automation systems for drug-substance manufacturing.
  • Lead a team of Automation Engineers and serve as the main point of contact for the automation function for manufacturing systems, including Allen Bradley programmable logic controllers, Siemens DesigoCC building automation, and Emerson DeltaV process control.
  • Define, drive, and deliver the automation and process-control strategy within drug-substance manufacturing.
  • Advise senior management and align the automation development strategy with the Amgen Process Development strategy.
  • Manage 24x7 operational support, mentoring, staff development, team productivity, and resource utilization.
  • Develop support structures with internal and multifunctional teams for capital projects, plant support, and network-level initiatives.
  • Provide input into department objectives and establish strategic direction for the drug-substance network automation team.
  • Maintain and improve automation-system capabilities and reliability in partnership with engineering, plant leadership, and technical staff, focusing on maintenance excellence, system failures, and recurrence avoidance.
  • Work with Manufacturing, Quality, Process Development, Automation, Technology, Environment, Health, Safety and Sustainability, and Global Engineering groups to drive new business processes and translate business needs into engineering technology solutions.
  • Lead alternatives analysis and recommendations for technical and business proposals.
  • Identify improvement opportunities, conduct analysis, recommend solutions, sponsor improvement projects, and implement them.
  • Ensure site readiness and compliance for internal, external-agency, and partner audits.
  • Ensure personnel safety during plant operations and engineering activities.
  • Develop expense-budget forecasts, adhere to department budgets, and maintain accountability for operational and capital expenses.
  • Maintain knowledge of compliance and regulatory requirements for operation and maintenance, equipment validation, and regulatory inspections and audits.
  • Maintain 100% compliance with Amgen enterprise cyber-resiliency requirements.
  • Ensure processes and systems capture quality compliance for right-first-time delivery of automation solutions.
  • Ensure reporting functionality for unit operations, production batch records, cleaning, and sterilization systems, including audit trails and version control.
  • Establish service contracts with original equipment manufacturers for system support, including banked service hours for specialized support.
  • Ensure automation staff are trained and follow Good Manufacturing Practice standards and procedures.
  • Ensure automation staff can work on automation systems, process equipment, and facilities to provide reliable 24x7 plant automation support.
  • Ensure the automation team participates in daily and weekly Work Center Team meetings to address operational topics and resolve issues with multifunctional teams.
  • Ensure the automation team supports expense, department-capital, construction, and GLAM-DTI projects.
  • Solicit proactive feedback from automation staff and take actions to maintain work-life balance.
Desired Qualifications
  • A degree in Electrical Engineering, Computer Science, Chemical Engineering, Biotech Engineering, or a related field.
  • Experience with Emerson DeltaV distributed control systems, Siemens DesigoCC, Allen Bradley programmable logic controllers, advanced troubleshooting, and system integration using OPC, Foundation Fieldbus, and Profibus technologies.
  • Direct knowledge of automation system design.
  • Experience programming, installing, and managing the lifecycle of automation and field-instrumentation technologies.
  • Experience automating Good Manufacturing Practice biopharmaceutical equipment and systems such as buffer preparation and hold, chromatography, single-use mixing vessels, depth filtration, and solution preparation.
  • Experience integrating automation software from various original equipment manufacturers.
  • Experience programming, designing, installing, and managing the lifecycle of manufacturing process controls, automation, and field-instrumentation technologies.
  • Knowledge of Fieldbus and Profibus technologies.
  • Ability to interpret and apply Good Automated Manufacturing Practice and Good Manufacturing Practice requirements, with familiarity with 21 CFR Part 11, ASTM E2500, S88, and S95 documentation.
  • Strong leadership, technical writing, and communication skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.